Abstract
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Abciximab
-
Acute Disease
-
Angina, Unstable / drug therapy
-
Angioplasty, Balloon, Coronary
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use*
-
Atherectomy
-
Clinical Trials as Topic*
-
Coronary Disease / drug therapy*
-
Coronary Disease / surgery
-
Coronary Disease / therapy
-
Eptifibatide
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage
-
Immunoglobulin Fab Fragments / therapeutic use
-
Myocardial Infarction / drug therapy
-
Peptides / administration & dosage
-
Peptides / therapeutic use
-
Placebos
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Stents
-
Syndrome
-
Time Factors
-
Tirofiban
-
Treatment Outcome
-
Troponin T / blood
-
Tyrosine / administration & dosage
-
Tyrosine / analogs & derivatives*
-
Tyrosine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Anticoagulants
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Peptides
-
Placebos
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Troponin T
-
Tyrosine
-
Tirofiban
-
Eptifibatide
-
Abciximab